Axicabtagene ciloleucel
Yescarta (axicabtagene ciloleucel) is a gene pharmaceutical. Axicabtagene ciloleucel was first approved as Yescarta on 2017-10-18. It has been approved in Europe to treat follicular lymphoma and large b-cell lymphoma diffuse.
| Trade Name | Yescarta |
|---|---|
| Common Name | Axicabtagene ciloleucel |
| Indication | follicular lymphoma, large b-cell lymphoma diffuse |
| Drug Class |
